The SynCardia temporary total artificial heart-evolving clinical role and future status

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


The SynCardia Temporary Total Artificial Heart (TAH) is the only clinically effective, Conformité Européene (CE) registered, Food and Drug Administration (FDA) approved and Centers for Medicare and Medicaid Services (CMS) reimbursed total artificial heart system available in the world today. The TAH is a complete, robust, pulsatile, biventricular replacement system indicated for use as a bridge to transplantation in cardiac transplant candidates at risk of imminent death from non-reversible biventricular failure. The TAH offers several advantages relative to present continuous flow left ventricular assist devices (LVADs), including higher 'quality' flow rates, reduced afterload and preload sensitivity, reduced thrombosis and stroke rates, and freedom from device-induced bleeding. More than 900 TAHs have been implanted to date, with a bridge-to-transplant success rate >79%. The availability of the new portable Freedom® driver has significantly enhanced patient mobility and made home discharge of patients possible. With home discharge, significant experience with long-term support on the TAH is now beginning to be accumulated. Technological advances continue to be imparted to the TAH system including portable driver enhancements, remote monitoring, and next-generation TAH designs.

Original languageEnglish (US)
Pages (from-to)39-46
Number of pages8
JournalUS Cardiology
Issue number1
StatePublished - 2011


  • Blood flow
  • Cardiac transplantation
  • Heart failure
  • Mechanical circulatory support
  • Pulsatility
  • Total artificial heart

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'The SynCardia temporary total artificial heart-evolving clinical role and future status'. Together they form a unique fingerprint.

Cite this